Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients,Annals of Neurology

当前位置： X-MOL 学术 › Ann. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
Annals of Neurology ( IF 11.2 ) Pub Date : 2020-03-09 , DOI: 10.1002/ana.25701
Peter Alping _{1,

2} , Johan Askling ₂ , Joachim Burman ₃ , Katharina Fink _{1,

4} , Anna Fogdell-Hahn ₁ , Martin Gunnarsson ₅ , Jan Hillert _{1,

6} , Annette Langer-Gould ₇ , Jan Lycke ₈ , Petra Nilsson ₉ , Jonatan Salzer ₁₀ , Anders Svenningsson ₁₁ , Magnus Vrethem ₁₂ , Tomas Olsson _{1,

4} , Fredrik Piehl _{1,

4} , Thomas Frisell ₂

Affiliation

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Department of Neuroscience, Uppsala University, Uppsala, Sweden.
Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden.
Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Pasadena, CA.
Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Sciences/Neurology, Lund University, Lund, Sweden.
Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Novel, highly effective disease‐modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking.

中文翻译：